Eiger BioPharmaceuticals

San Carlos, United States Founded: 2000 • Age: 26 yrs Listed
Developer of antiviral agents against targets in the treatment of hepatitis

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals is a publicly listed company based in San Carlos (United States) founded in 2000. Eiger BioPharmaceuticals has raised $8.9 million across 7 funding rounds from investors including RA Capital, Perceptive Advisors and HBM Healthcare Investments. The company has 56 employees. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its competitors include Spark Therapeutics, Denali Therapeutics and AskBio; 3 of its 3 listed competitors have raised funding.

Company details

Developer of antiviral agents against targets in the treatment of hepatitis. It offers a lead product candidate, avexitide a first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism

  • Headquarters San Carlos, United States
  • Employees 56
  • Stage Public
  • Sectors
    Healthcare
  • Website eigerbio.com
  • Social LinkedIn
Key Metrics
  • Annual Revenue
    $15.77 M (USD)
    17
    as on Dec 31, 2023
  • Net Profit
    -$74.96 M (USD)
    23
    as on Dec 31, 2023
  • EBITDA
    -$71.79 M (USD)
    23
    as on Dec 31, 2023
  • Total Equity Funding
    $8.9M (USD)

    in 7 rounds

  • Latest Funding Round
    $3M (USD), Post-IPO

    Apr 2019

  • Investors
    RA Capital

    & 6 more

  • Employee Count
    56

Funding Insights of Eiger BioPharmaceuticals

Eiger BioPharmaceuticals has successfully raised a total of $8.9M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $3 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $8.9M
  • Total Rounds 7
  • Last Round Post-IPO โ€” $3M
  • First Round $8.3M

    (Sep 2010)

  • Investors Count 7

All 7 funding rounds of Eiger BioPharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2019$3MPost-IPOโ€“โ€“
โ€“
Mar 2016$39.5MPost-IPOโ€“โ€“
Nov 2015$6MPost-IPOโ€“โ€“
โ€“
Mar 2015$14.46MPost-IPOโ€“โ€“
โ€“
Oct 2011$200,000Series Aโ€“โ€“
โ€“
Jul 2011$400,000Series Aโ€“โ€“
โ€“
Sep 2010$8.3MSeries Aโ€“InterWest Partners, Vivo Capital
โ€“
Valuation history

7 investors in total: 7 institutional.

Investors in Eiger BioPharmaceuticals

Eiger BioPharmaceuticals has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, Perceptive Advisors and HBM Healthcare Investments.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Life sciences focused VC firm funding companies in the US and Europe
2001hbmhealthcare.comZug, Switzerland
Venture capital and private equity firm
vivocapital.comPalo Alto, United States
Early-stage investing in IT and healthcare ventures.
interwest.com
Health-tech companies are targeted for venture capital investments.
1999perceptivelife.comNew York, United States
RA Capital is engaged in evidence-based investing in healthcare and life sciences.
2004racap.comBoston, United States
spheraglobalhealthcare.com
monasheecapital.com
Premium access

Investor details for Eiger BioPharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Eiger BioPharmaceuticals

18 people are tracked at Eiger BioPharmaceuticals (9 in leadership, 7 in board & advisors, 2 in team); the tracked headcount is 56.

NameRoleGroup
Bradford Lees
Director Of AccountingLeadership
James Vollins
General Counsel, Chief Compliance Officer & Corporate SecretaryLeadership
Monica Gangal
Vice President Clinical OperationsLeadership
William Kaichoff
CFOLeadership
David Apelian
CEOLeadership
Christopher Kurtz
Chief Technical OfficerLeadership
Sandy Leng, CPA
Director Of AccountingLeadership
Matthew Bys
Executive Director, Chief Of StaffLeadership
Piper Q.
Senior Director, Human ResourcesLeadership
Christine Murray
Independent DirectorBoard & advisors
Jeffrey S. Glenn
Director, Scientific FounderBoard & advisors
Amit K. Sachdev
Independent DirectorBoard & advisors
Thomas J. Dietz
ChairmanBoard & advisors
Evan Loh
Independent DirectorBoard & advisors
Lisa Kelly-Croswell
Independent DirectorBoard & advisors
Kim Sablich
DirectorBoard & advisors
Colin Hislop
SVP, Clinical & Development OperationsTeam
Ingrid Choong
SVP, Clinical DevelopmentTeam
Premium access

Complete people profiles for Eiger BioPharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Eiger BioPharmaceuticals

4 dated milestones of Eiger BioPharmaceuticals across 19 years, from founding to its latest funding, stage changes and deals.

  1. Founded Eiger BioPharmaceuticals is founded.
  2. Funding First funding round of $8.3M.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO, of $3.0M.

Competitors of Eiger BioPharmaceuticals

Eiger BioPharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Spark Therapeutics, Denali Therapeutics and AskBio.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
sparktx.com2013Philadelphia, United States$82.8M822
Gene therapies for rare diseases including retinal dystrophies are developed.
denalitherapeutics.com2015San Francisco, United States$347M377
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
askbio.com2001Durham, United States$235M
Gene and protein therapies are developed for treating various diseases.
Premium access

Detailed competitors of Eiger BioPharmaceuticals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Eiger BioPharmaceuticals (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track โ€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • โœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • โœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • โœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Eiger Biopharmaceuticals

Premium access

Complete news archive for Eiger BioPharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Eiger BioPharmaceuticals

Eiger BioPharmaceuticals was founded in 2000 and raised its 1st funding round 10 years after it was founded.

Eiger BioPharmaceuticals is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.

Eiger BioPharmaceuticals is a funded company, having raised a total of $8.9M across 7 funding rounds to date. The company's 1st funding round was a Series A of $8.3M, raised on Sep 2010.

Eiger BioPharmaceuticals has 56 employees.

Annual revenue of Eiger BioPharmaceuticals is $15.77M as on Dec 31, 2023.

Developer of antiviral agents against targets in the treatment of hepatitis. It offers a lead product candidate, avexitide a first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism.

Eiger BioPharmaceuticals's top competitors include Spark Therapeutics, AskBio and Denali Therapeutics.

Eiger BioPharmaceuticals has 7 investors. Key investors include RA Capital, Perceptive Advisors, HBM Healthcare Investments, Vivo Capital, and InterWest.

Explore millions of companies โ€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals โ€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available